EYPT Q4 2024 Earnings — EyePoint Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

EYPTEyePoint Pharmaceuticals, Inc.

$1B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$12M-17.4% YoY

Gross Profit

$11M93.0% margin

Operating Income

-$45M-390.4% margin

Net Income

-$41M-357.3% margin

EPS (Diluted)

$-0.64

QoQ Revenue Growth

+10.1%

Cash Flow

Operating Cash Flow

-$36M

Free Cash Flow

-$36M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$418M

Total Liabilities

$82M

Stockholders' Equity

$337M

Cash & Equivalents

$100M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$12M	$14M	-17.4%
Gross Profit	$11M	$13M	-17.3%
Operating Income	-$45M	-$16M	-176.6%
Net Income	-$41M	-$14M	-193.6%

Revenue Segments

License And Collaboration Agreement

$21M86%

Product

$1M6%

Y U T I Q Product

$1M5%

Royalty

$687,0003%